Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.57 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.41 |
| ▸ | DPP4 | P27487 | 5/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | ARG2 | P78540 | 4/20 | 0.38 |
| ▸ | ARG1 | P05089 | 3/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL5227175 | 1.00 | GSR (0.57) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL4296375 | 1.00 | GSR (0.57) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL28079281 | 1.00 | GSR (0.57) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL1537262 | 1.00 | GSR (0.57) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL11660661 | 1.00 | GSR (0.57) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL23834597 | 1.00 | GSR (0.57) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL8520187 | 0.99 | GSR (0.56) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL21796038 | 0.96 | GSR (0.53) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL22157986 | 0.96 | GSR (0.53) | GSRDPP7DPP4DPP8DPP9 | |
| Lysine SCHEMBL1675387 | 0.96 | GSR (0.53) | GSRDPP7DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3544992-A1 | G-PROTEIN-COUPLED RECEPTOR INTERNAL SENSORS | The Regents of The University of California (US) | 2019-10-02 | — | — | EP | claimed |
| WO-2018098262-A1 | G-PROTEIN-COUPLED RECEPTOR INTERNAL SENSORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-31 | — | — | WO | claimed |
| EP-3326625-A1 | SYSTEMS, METHODS, AND FORMULATIONS FOR TREATING CANCER | Research Cancer Institute of America (US) | 2018-05-30 | — | — | EP | claimed |
| WO-2017210242-A1 | INSULIN-NUCLEAR HORMONE CONJUGATES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-12-07 | — | — | WO | claimed |
| EP-3206710-A1 | INCRETIN-INSULIN CONJUGATES | Indiana University Research & Technology Corporation (US) | 2017-08-23 | — | — | EP | claimed |
| EP-3197912-A1 | LIPIDATED AMIDE-BASED INSULIN PRODRUGS | Indiana University Research & Technology Corporation (US) | 2017-08-02 | — | — | EP | claimed |
| EP-2729008-B1 | SYSTEMS, METHODS, AND FORMULATIONS FOR TREATING CANCER | RES CANCER INST OF AMERICA (US) | 2017-04-05 | — | — | EP | claimed |
| US-20170007573-A1 | METHOD OF TREATING CANCER WITH COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS (HDAC1) SUBSTANCES | RESEARCH CANCER INSTITUTE OF AMERICA | 2017-01-12 | — | — | US | claimed |
| WO-2016049190-A1 | INCRETIN-INSULIN CONJUGATES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-03-31 | — | — | WO | claimed |
| WO-2016049174-A1 | LIPIDATED AMIDE-BASED INSULIN PRODRUGS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-03-31 | — | — | WO | claimed |
| WO-2013006821-A1 | SYSTEMS, METHODS, AND FORMULATIONS FOR TREATING CANCER | RESEARCH CANCER INSTITUTE OF AMERICA (US) | 2013-01-10 | — | — | WO | claimed |
| US-20130011488-A1 | Systems, Methods, and Formulations for Treating Cancer | RESEARCH CANCER INSTITUTE OF AMERICA | 2013-01-10 | — | — | US | claimed |
| WO-2011159895-A2 | SINGLE CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2011-12-22 | — | — | WO | claimed |
| EP-2376099-A1 | YL-BASED INSULIN-LIKE GROWTH FACTORS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | Indiana University Research & Technology Corporation (US) | 2011-10-19 | — | — | EP | claimed |
| WO-2010080607-A1 | YL-BASED INSULIN-LIKE GROWTH FACTORS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2010-07-15 | — | — | WO | claimed |
| EP-1796701-A1 | COMPOSITIONS FOR ANTI-OBESITY, HEALTH-RESTORATIVE AND HEALTH-PROMOTIONAL BENEFITS | Natreon Inc. (US) | 2007-06-20 | — | — | EP | claimed |
| US-7041699-B2 | Nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer | MATTHIAS RATH (US) | 2006-05-09 | — | — | US | claimed |
| WO-2006036638-A1 | COMPOSITIONS FOR ANTI-OBESITY, HEALTH-RESTORATIVE AND HEALTH-PROMOTIONAL BENEFITS | NATREON, INC. (US) | 2006-04-06 | — | — | WO | claimed |
| US-20060062863-A1 | Compositions for anti-obesity, health-restorative and health-promotional benefits | NATREON INC. | 2006-03-23 | — | — | US | claimed |
| US-20050090480-A1 | Use of selected amino acid-zinc complexes as anti-malarials | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2005-04-28 | — | — | US | claimed |